National HIV treatment guidelines have evolved greatly in the past decade. Current guidelines recommend early initiation of antiretroviral treatment (eiART) and baseline drug resistance testing (bDRT) upon diagnosis and linkage to care. bDRT and eiART patterns were assessed with respect to national treatment guidelines.
San Francisco residents diagnosed with HIV/non-AIDS between 2001 and 2012 who were linked to care at publicly-funded facilities were included in the analysis (N=2,565). Cases were stratified by era of treatment guidelines based on diagnosis year: Era 1=2001-03 (n=657), Era 2=2004-06 (n=716), Era 3=2007-09 (n=640) and Era 4=2010-12 (n=552). bDRT and eiART were defined as occurring within 3 months of diagnosis.
The proportion of cases with bDRT increased from 2001 to 2012 (p<0.001). The nadir was 4% in 2001, increased to 9% in 2002, dipped to 8% in 2003, rose to 12% in 2004, and then continued to increase to a peak of 56% in 2012. bDRT increased across the 4 eras, from 7% to 15% to 33% to 49% (p<0.001). The proportion of cases with eiART increased from 2001 to in 2012 (p<0.001). The proportion was 16% in 2001, decreased over the next 3 years to a nadir of 4% in 2004, and then began to increase steadily to a peak of 45% in 2012. eiART increased across the 4 eras, from 11% to 6% to 16% to 36% (p<0.001). eiART was associated with an increased likelihood of bDRT (p<0.001). Gender, age, race/ethnicity and HIV transmission risk were not associated with bDRT overall; persons <20 years and Latinos were more likely to have been tested in Era 4 (p<0.05).
Baseline drug resistance testing increased steadily from 2004 to 2012, though not all genotyped cases initiated treatment within 3 months of diagnosis. Nevertheless, baseline genotyping can be useful for informing regimen selection upon the subsequent decision to initiate ART, since a transmitted resistant mutant present early in the course of infection may still be in viral archives but no longer detectable as the most abundant variant. eiART increased substantially in Era 4 which may reflect the adoption of treatment as prevention, whereas the observed decrease in late Era 1 and in Era 2 may stem from concerns during that time about the toxicities associated with ART. Lack of disparities in baseline drug resistance testing by demographic or risk group may be due to federal and municipal support that facilitated access to primary care services.